This website uses tracking technologies, such as cookies, to provide a better user experience. If you continue to use this site, then you acknowledge our use of tracking technologies. For additional information, review our Privacy Policy.
Checkpoint immunotherapies have helped many patients by enabling their immune cells to stay active against cancer. Checkpoint immunotherapies can sometimes reinvigorate “exhausted” cells, but not always. Dr. Abdel Hakeem wants to understand what controls this exhaustion, specifically at the epigenetic level (where genes are turned on/off). Using a viral model called LCMV, he’s exploring epigenetic patterns associated with exhaustion that might suggest other ways to prevent and reverse it. These strategies might also work well with current checkpoint therapies and help provide patients with even better outcomes.
University of Pennsylvania School of Medicine | All Cancers, Lung Cancer, Melanoma | 2016 | E. John Wherry, Ph.D.
Contact Us
Cancer Research Institute | National Headquarters 29 Broadway, Floor 4 | New York, NY 10006-3111
800-992-2623212-832-9376Staff Directory
A recent diabetes-related discovery by CRI Lloyd J. Old STAR Dr. Andrea Schietinger has promising implications for cancer immunotherapy
Rare and ultra-rare cancers affect around 20,000 people in the United States alone, according to Foundation Medicine, Inc. Immunotherapy research in some of the more common cancers and the identification of biomarkers that can predict patient responses is opening this new approach to cancer treatment up to patients whose cancers currently receive little direct attention.